Clinical Development & Data
Trial architecture, endpoints, recruitment, comparator signals, investigator interpretation, and the way evidence in endocrinology will be read downstream.
Endocrinology
ICG works across endocrinology environments where chronic evidence, metabolic outcomes, specialist and primary-care pathways, delivery devices, reimbursement, and field organization interact.
The work includes endocrinology competitive intelligence, diabetes, obesity, growth and hormone disorders, metabolic liver disease, glucose monitoring and injection systems, market access, launch, and longitudinal monitoring.
Chronic Biology Meets Daily Operating Reality.
Endocrine markets are governed by long-term outcomes, patient segmentation, primary and specialist care, adherence, monitoring, device ecosystems, reimbursement, and the capacity of organizations to operate at scale.
ICG reconstructs how those conditions shape development, clinical position, access, delivery, launch, and portfolio choices.
Decision Environments
Engagements begin at different points, but the governing constraints often cross the boundaries of the initial request.
Regulatory & Access Pathways
Filing logic, label conditions, evidence requirements, reimbursement, pathway position, and country-level adoption constraints.
Launch & Commercial Architecture
Market preparation, field-force and medical roles, account coverage, channel structure, patient support, and launch sequencing.
Manufacturing & Delivery
Capacity, supply, configuration, administration, device or site readiness, and the relationship between operational uncertainty and asset value.
Patient & Treatment Systems
Patient identification, referral patterns, specialist pathways, administration burden, monitoring, persistence, and continuity of treatment.
Longitudinal Competitive Monitoring
Clinical, regulatory, access, organization, and commercial signals reconstructed across multi-phase and multi-year programs.
Evidence Architecture
The evidence base is developed through source calls and interviews positioned close to the decisions, constraints, and operating conditions being reconstructed.
Clinical & Investigator Side
Key opinion leaders, principal investigators, study-site personnel, treating specialists, centers of excellence, diagnostic pathways, and investigator-side clinical teams.
Company-Side Sources
Clinical development, regulatory, medical affairs, CMC and manufacturing, market access, patient services, field leadership, commercial, and portfolio functions.
Access & Operating Systems
Payer and reimbursement environments, procurement, distribution, treatment centers, testing providers, administration systems, patient-support infrastructure, and local access pathways.
Triangulation
Interview evidence is tested against clinical, regulatory, manufacturing, access, and organizational signals and against the criteria used by reviewers, payers, clinicians, partners, and other decision-makers.
Selected Project Record
Selected engagements across endocrinology.
The projects below are selected from a substantially larger body of work. They were chosen to illustrate different decision environments, lifecycle stages, modalities, geographies, and forms of engagement. The selection is illustrative rather than exhaustive. Multi-phase and longitudinal assignments may be presented as a single project title, and company, asset, or market details may be generalized where appropriate.
Clinical Development & Data
- Clinical-Development and Commercial Assessment of Oral and Injectable Incretin Therapies
- Competitive Development Assessment Across Obesity and Type 2 Diabetes Portfolios
- Clinical and Regulatory Assessment of Therapies in Growth-Hormone Deficiency
- Development Landscape for Therapies in Hypoparathyroidism
- Clinical-Development Assessment of Therapies in Metabolic Liver Disease
Regulatory, Access & Adoption
- Market-Access and Reimbursement Architecture for Obesity Therapies
- Payer and Prescriber Response to Incretin Therapies in Europe and the United States
- Access and Adoption Assessment for Continuous Glucose Monitoring Systems
- Reimbursement and Treatment-Pathway Assessment for Rare Endocrine Therapies
- Market-Entry Assessment for Diabetes Portfolios in Italy and Selected European Markets
Launch & Commercial Architecture
- Launch and Field-Organization Architecture for Diabetes and Obesity Portfolios
- Commercial Assessment of Long-Acting Growth-Hormone Therapies
- Field-Force Benchmarking Across Diabetes Portfolios in Europe
- Launch Strategy for Therapies in Acromegaly
- Commercial Architecture for Glucagon and Rescue-Therapy Markets
Manufacturing, Delivery & Systems
- Continuous-Glucose-Monitoring and Sensor Landscape
- Cost and Manufacturing Assessment for Diabetes Devices
- Injection-Device and Connected-Care Architecture in Diabetes
Longitudinal Monitoring & Portfolio
- Longitudinal Monitoring Across Obesity and Type 2 Diabetes Portfolios
- Portfolio Monitoring Across Growth, Hormone and Metabolic Disorders
Endocrinology Engagements
ICG can enter at the level of a single critical question, a multi-market evidence program, or a longitudinal clinical, regulatory, manufacturing, access, commercial, or operating-system decision environment.